Isabela Pedroza-Pacheco

Immunology Vaccines Prevention Diagnostic Treatment cancer infectious diseases @NDMOxford

[Isabela Pedroza-Pacheco @IPedrozaPacheco]

We are delighted to announce our work with IPN and HGMEL, which will provide an exciting opportunity to understand the immunological link between diet and lifestyle in Mexican patients with bowel cancer.

[Once Noticias @OnceNoticiasTV]

🎦@IPN_MX y la @UniofOxford firmaron el acuerdo para un proyecto de investigación enfocado en la detección de mutaciones en pacientes mexicanos. @rubenfieytal tiene la información.

@lumiery y @zanzittle en #OnceNoticiasMatutino🔻

[Isabela Pedroza-Pacheco @IPedrozaPacheco]

Great science at Westgate!

[Ester Gea-Mallorquí @estergeama]

Come see our Centre for Immuno-Oncology @OxImmuno @OxfordCancer stand at Westgate @OxfordBRC event 👩‍🔬👨‍🔬 You can even pipette and “flow” some samples just like our director is doing here @tim_tje 😁

[Eric Topol @EricTopol]

Good thing it's so simple to predict optimal vaccine response ;-)
https://t.co/bMLu6L5YGB
A molecular/cellular dissection for why some people have better antibody responses than others, summary of 2 recent reports @NatRevImmunol by @IPedrozaPacheco @NDMOxford

[HIPC @hipcProject]

Authors @IPedrozaPacheco and Andrew McMichael praise insights from #systems #immunology in two recent papers from our @hipcproject. (1,n)
@NatImmunol
https://t.co/RpmuclnYY3

[BSI Congress & Events @bsicongress]

#BSI22 satellite symposium sponsored by @BioRad 💫

Dr @IPedrozaPacheco will discuss the immunological environment associated with development of bnAbs in #HIV1 infection to inform #vaccine design

More info 👉https://t.co/m10QRcEYJL

[Isabela Pedroza-Pacheco @IPedrozaPacheco]

Very nice paper about receptor-ligand interactions!
https://t.co/hMx5IEyv91

[Prof. Shane Crotty @profshanecrotty]

At this point, you are either vaccinated or you are going to catch Delta.
And whether you are young adult or old, when you catch Delta unvaccinated, you will have the highest chance of being hospitalized compared to almost any disease you have caught in your life.

[Andrew Pollard @ajpollard1]

A standing ovation today on centre court @Wimbledon for the #COVID19Vaccine. Applause for science, scientists and the public who take part in research @NIHRresearch @UniofOxford

[Science Immunology @SciImmunology]

"The single cell #transcriptomics approach confirmed that many developmental events described in mice are maintained in human T follicular regulatory cells, in addition to unique human features not yet described in mice." @lgraca, @saum_kmr on their study: https://t.co/o7UerLCU55

[Isabela Pedroza-Pacheco @IPedrozaPacheco]

The HIV Keystone Meeting starts today!!. Tune in to explore emerging #HIV #VaccineResearch and hear the latest science from outstanding HIV scientists around the world #VKSHIVVax21.

[Isabela Pedroza-Pacheco @IPedrozaPacheco]

👇Bringing Journal Club to the next level. Check out the OxMS initiative by Oxford and Mt Sinai immunology units. Follow @preprintclub for updates on great science.

[Preprint Club - Immunology @preprintclub]

Interested in #Immunology ?

#Students and #Postodocs from @OxImmuno and @SinaiImmunol summarize the most interesting #preprints after presenting them on our #JournalClub

Every month, we publish two comments at @NatRevImmunol

Check our website 👇🤓
https://t.co/3vicQggttj

[Preprint Club - Immunology @preprintclub]

What were our favourite #preprints in March? 👇

[Mauri Lab UCL @Mauri_group]

Excited to share our first preprint showing that patients with SLE that develop anti-IFNa autoantibodies have improved clinical outcomes 💪 in collaboration with the amazing @MadhviM and @kai_kisand and many other great colleagues 🙌🎉👩‍🔬🔬
https://t.co/9SjB0o4vMh

[Isabela Pedroza-Pacheco @IPedrozaPacheco]

Sensitive force measurements are now possible in immune cells🏋🏼‍♀️. Check out this exciting work by @FritzscheLab.

[Fritzsche M et al @FritzscheLab]

We @FritzscheLab developed exciting new 2D and 2.5D #TFM methods 🥳 @NatureComms:
https://t.co/yyG906LKKc
https://t.co/gwr0OuFZMo

Thx to HCY @barbieri_lili @Snusmumrik_K @faldalf @KaredlaNarain @emadmoeen @MichaelLDustin @MRC_HIU @KirOxford @NDORMS @UniofOxford @RosFrankInst

[Wellcome Sanger Institute @sangerinstitute]

This project will be lead by an international team of experts, including Sanger International Fellow @daniela_oaks.

Learn about how she began her scientific career milking scorpions to study anti-venoms, and is now a PI studying #melanoma 👩🏻‍🔬🔬⤵️

https://t.co/95Y3hLF96K

[Eric Topol @EricTopol]

If the vaccine approach turns out to be an effective treatment for #LongCovid (alleviating symptoms in a significant proportion) that would turn out to be an unexpected bonus. A big unmet need and high priority for research now.
Let's hope it works.
Thanks @VirusesImmunity

[Diana Berrent Güthe @dianaberrent]

One of the grassroots organizations at the forefront is @Survivor_Corps, which to date has attracted more than 157,000 COVID survivors to its @Facebook group.

#LongCovid @VirusesImmunity
What If COVID Is Chronic? https://t.co/YVnyCbasec #HealthCentral via @HealthCentral

[Cell @CellCellPress]

Today’s #FacesOfCell is Luis Fernando Camarillo-Guerrero @LuisF_Camarillo. Read his @CellCellPress paper “Massive expansion of human gut bacteriophage diversity” https://t.co/rq8kwbe63f

[Eric Topol @EricTopol]

After covid-19, ~1% of people make extremely potent neutralizing antibodies https://t.co/170DUbOdpq @CellCellPress 1/453 nAbs potent vs emerging variants (N501Y, E484K). Lessons from nature as foundation for rational design of universal vaccines

[Eric Topol @EricTopol]

New on 1-dose @Pfizer vaccine after prior covid
"We show that individuals with previous #SARSCoV2 infection generate strong humoral and cellular responses to one dose of BNT162b2 vaccine, with evidence of high titres of in-vitro live virus neutralisation"
https://t.co/2G7TRu57OI